Evidence map›Paper›PMID 23318904›Full record

ArticleEuropean journal of medicinal chemistry2013

Design, synthesis and biological evaluation of sulfur-containing 1,1-bisphosphonic acids as antiparasitic agents.

Marion Recher, Alejandro P Barboza, Zhu-Hong Li, Melina Galizzi, Mariana Ferrer-Casal, Sergio H Szajnman, Roberto Docampo, Silvia N J Moreno, Juan B Rodriguez

Open access · bronzeAbstract read
In one paragraph

Article in European journal of medicinal chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.6field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 52 citations in OpenAlex.

  1. Legacy 4(1ACS infectious diseases · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Multi-target heteroleptic palladium bisphosphonate complexes.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2020
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Marion RecherDepartamento de Química Orgánica and UMYMFOR (CONICET-FCEyN), Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Pabellón 2, Ciudad Universitaria, C1428EHA Buenos Aires, Argentina.
Alejandro P Barboza
Zhu-Hong Li
Melina Galizzi
Mariana Ferrer-Casal
Sergio H Szajnman
Roberto Docampo
Silvia N J Moreno
Juan B Rodriguez
University of Buenos Aires · ARUniversity of Georgia · USFundación Ciencias Exactas y Naturales · AR

Funding

Drug Discovery Consortium for Chagas DiseaseR01AI082542 · NIAID · UNIVERSITY OF GEORGIA · PI TARLETON, RICK L · 2009 to 2010
$2.2M
Targeting Host and Apicomplexan Isoprenoid PathwaysR33AI102254 · NIAID · UNIVERSITY OF GEORGIA · PI MORENO, SILVIA N · 2014 to 2016
$1.3M
Targeting Host and Apicomplexan Isoprenoid PathwaysR21AI102254 · NIAID · UNIVERSITY OF GEORGIA · PI MORENO, SILVIA N · 2012 to 2013
$408k
The isoprenoid pathway from Toxoplasma gondiiR21AI068467 · NIAID · UNIVERSITY OF GEORGIA · PI MORENO, SILVIA N · 2006 to 2007
$400k
NIAID NIH HHS AI-068467NIAID NIH HHS AI-082542NIAID NIH HHS R01 AI082542NIAID NIH HHS R21 AI102254NIAID NIH HHS R33 AI102254
6 · The paper itself

Abstract

As part of our efforts aimed at searching for new antiparasitic agents, 2-alkylmercaptoethyl-1,1-bisphosphonate derivatives were synthesized and evaluated against Trypanosoma cruzi, the etiologic agent of Chagas disease, and Toxoplasma gondii, the responsible agent for toxoplasmosis. Many of these sulfur-containing bisphosphonates were potent inhibitors against the intracellular form of T. cruzi, the clinically more relevant replicative form of this parasite, and tachyzoites of T. gondii targeting T. cruzi or T. gondii farnesyl diphosphate synthases (FPPSs), which constitute valid targets for the chemotherapy of these parasitic diseases. Interestingly, long chain length sulfur-containing bisphosphonates emerged as relevant antiparasitic agents. Taking compounds 37, 38, and 39 as representative members of this class of drugs, they exhibited ED(50) values of 15.8 μM, 12.8 μM, and 22.4 μM, respectively, against amastigotes of T. cruzi. These cellular activities matched the inhibition of the enzymatic activity of the target enzyme (TcFPPS) having IC(50) values of 6.4 μM, 1.7 μM, and 0.097 μM, respectively. In addition, these compounds were potent anti-Toxoplasma agents. They had ED(50) values of 2.6 μM, 1.2 μM, and 1.8 μM, respectively, against T. gondii tachyzoites, while they exhibited a very potent inhibitory action against the target enzyme (TgFPPS) showing IC(50) values of 0.024 μM, 0.025 μM, and 0.021 μM, respectively. Bisphosphonates bearing a sulfoxide unit at C-3 were also potent anti-Toxoplasma agents, particularly those bearing long aliphatic chains such as 43-45, which were also potent antiproliferative drugs against tachyzoites of T. gondii. These compounds inhibited the enzymatic activity of the target enzyme (TgFPPS) at the very low nanomolar range. These bisphosphonic acids have very good prospective not only as lead drugs but also as potential chemotherapeutic agents.

Indexed as

Drug DesignAntiprotozoal AgentsDiphosphonatesDose-Response Relationship, DrugMolecular StructureParasitic Sensitivity TestsStructure-Activity RelationshipSulfurToxoplasmaTrypanosoma cruziAntiprotozoal AgentsDiphosphonatesSulfur

Identifiers

PMID23318904
PMCPMC3582829
OpenAlexW1997239486

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.